{"id":"W2984884245","doi":"10.1016/j.eururo.2019.10.002","title":"Efficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR)","year":2019,"lang":"en","type":"article","venue":"European Urology","topic":"Urinary Bladder and Prostate Research","field":"Medicine","cited_by":78,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; University of Alberta","funders":"Pfizer Canada; Astellas Pharma Global Development; Astellas Pharma; Astellas Pharma Canada","keywords":"Medicine; Tolerability; Overactive bladder; Mirabegron; Placebo; Urology; Pillar; Double blind; Safety profile; Adverse effect; Surgery; Internal medicine; Pathology","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001807632,0.001369505,0.003307151,0.0005393598,0.000519148,0.0009661001,0.0007082644,0.001663381,0.005134454],"category_scores_gemma":[0.001536191,0.0008310605,0.001926877,0.0004803739,0.0007897358,0.0009863714,0.0004214479,0.002135557,0.0008190906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003596658,"about_ca_system_score_gemma":0.0008842335,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005880744,"about_ca_topic_score_gemma":0.001294752,"domain_scores_codex":[0.9994392,0.0002541582,0.00006315309,0.00009970533,0.0000519945,0.00009180171],"domain_scores_gemma":[0.9990309,0.0001940004,0.0002955543,0.00006490595,0.00009135024,0.0003232294],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9404414,0.02100632,0.002008837,0.001640743,0.001221136,0.00006459595,0.0001203944,0.0001844419,0.006691024,0.00004087653,0.0006503933,0.0259298],"study_design_scores_gemma":[0.824549,0.1668461,0.006861923,0.0000601741,0.0004752401,0.00003801346,0.00003249888,0.0001288056,0.0003346673,0.00003683115,0.0006186193,0.00001821418],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9838967,0.008333328,0.0004928128,0.0003744086,0.0003214304,0.004552245,0.0008498905,0.00009950065,0.001079704],"genre_scores_gemma":[0.9810085,0.005595638,0.00206254,0.001534075,0.0006770545,0.005944241,0.0009943814,0.0000209604,0.002162568],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005134454,"threshold_uncertainty_score":0.01717651,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02021618769318475,"score_gpt":0.3040407910611911,"score_spread":0.2838246033680064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}